ERBB2 and breast cancer: Second, we undertook an open‐label, phase 2 study of colon pathology via colonoscopy‐based imaging and biopsies in patients receiving neratinib for HER2‐positive BC to examine if any pathological changes observed in patients were concordant with the observations made in the rodent model.